Scalper1 News
Regeneron Pharmaceuticals beat analysts’ Q4 estimates and guided this year’s drug sales in line with views Tuesday, and also said it’s building a new facility in low-tax Ireland. The stock popped to a new high, closing up 7.4% at 326.52. Regeneron’s (REGN) sales in the quarter totaled $610 million, up 47% from the year-earlier quarter and $29 million more than analysts’ consensus. Non-GAAP net income rose 52% to $2.24 a share. Analysts’ estimates Scalper1 News
Scalper1 News